Our results highlight the possibility that suppression of TGF-β signaling by miR-26-5p could be beneficial for the “fitness” of the leukemic clone and suggest that TGF-β pathway modulation could become an alternative strategy to explore in CLL therapy. The gene discussed is TGFB1; the disease is B-cell chronic lymphocytic leukemia.